BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/6/2021 11:18:51 AM | Browse: 401 | Download: 754
 |
Received |
|
2021-01-21 01:54 |
|
Peer-Review Started |
|
2021-01-21 01:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-25 02:29 |
|
Revised |
|
2021-02-26 18:32 |
|
Second Decision |
|
2021-04-16 12:49 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-04-21 03:59 |
|
Articles in Press |
|
2021-04-21 03:59 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-04-27 15:53 |
|
Publish the Manuscript Online |
|
2021-05-06 11:18 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Minireviews |
| Article Title |
Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
William de Jesús Ríos-Ríos, Sorely Adelina Sosa-Luis and Honorio Torres-Aguilar |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| A basic science grant from CONACyT |
285480 |
| the Department of Clinical Immunology Research of the Biochemical Sciences Faculty |
|
|
| Corresponding Author |
Honorio Torres-Aguilar, PhD, Professor, Department of Biochemical Sciences Faculty, Universidad Autónoma “Benito Juárez” de Oaxaca, Av. Universidad S/N Ex-Hacienda 5 Señores, Oaxaca 68120, Mexico. qbhonorio@hotmail.com |
| Key Words |
Type 1 diabetes; Dendritic cells; Autoimmunity; Immune tolerance; Cell therapy; Immunotherapy. |
| Core Tip |
Autoimmunity in type 1 diabetes (T1D) is severe and leads to pancreatic dysfunction; therefore, therapies that can lessen this process are required. Cell therapy with tolerogenic dendritic cells (tolDCs) is a promising strategy. Various protocols have been implemented for tolDC generation, using stimuli such as cytokines, growth factors, and drugs. These cells are also subjected to treatments with antisense oligonucleotides, liposomes, toll-like receptor ligands, and peptides of the pancreatic islets, for optimization as T1D immunotherapy. Preclinical and clinical trials have demonstrated effectiveness of tolDC-based therapy. This review aims to give a detailed understanding of current advances in tolDC-based T1D treatment. |
| Publish Date |
2021-05-06 11:18 |
| Citation |
Ríos-Ríos WJ, Sosa-Luis SA, Torres-Aguilar H. Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes. World J Diabetes 2021; 12(5): 603-615 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i5/603.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i5.603 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
